173 related articles for article (PubMed ID: 33237904)
1. Blood pressure and bladder cancer risk in men by use of survival analysis and in interaction with NAT2 genotype, and by Mendelian randomization analysis.
Teleka S; Hindy G; Drake I; Poveda A; Melander O; Liedberg F; Orho-Melander M; Stocks T
PLoS One; 2020; 15(11):e0241711. PubMed ID: 33237904
[TBL] [Abstract][Full Text] [Related]
2. Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three Swedish cohorts.
Teleka S; Jochems SHJ; Häggström C; Wood AM; Järvholm B; Orho-Melander M; Liedberg F; Stocks T
Cancer Med; 2021 Feb; 10(4):1431-1438. PubMed ID: 33455057
[TBL] [Abstract][Full Text] [Related]
3. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women.
Teleka S; Häggström C; Nagel G; Bjørge T; Manjer J; Ulmer H; Liedberg F; Ghaderi S; Lang A; Jonsson H; Jahnson S; Orho-Melander M; Tretli S; Stattin P; Stocks T
Int J Cancer; 2018 Dec; 143(12):3071-3082. PubMed ID: 29756343
[TBL] [Abstract][Full Text] [Related]
4. The interaction between smoking and bladder cancer genetic variants on urothelial cancer risk by disease aggressiveness.
Teleka S; Jochems SHJ; Jirström K; Stocks T
Cancer Med; 2022 Aug; 11(15):2896-2905. PubMed ID: 35285182
[TBL] [Abstract][Full Text] [Related]
5. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk.
Elsalem L; Al Shatnawi A; A Alfaqih M; Alshoh A; Al Demour S; Al-Daghmin A; Halalsheh O; Kheirallah K; Ahram M
Acta Biochim Pol; 2023 Aug; 70(3):575-582. PubMed ID: 37595067
[TBL] [Abstract][Full Text] [Related]
7. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
8. rs1495741 as a tag single nucleotide polymorphism of N-acetyltransferase 2 acetylator phenotype associates bladder cancer risk and interacts with smoking: A systematic review and meta-analysis.
Ma C; Gu L; Yang M; Zhang Z; Zeng S; Song R; Xu C; Sun Y
Medicine (Baltimore); 2016 Aug; 95(31):e4417. PubMed ID: 27495060
[TBL] [Abstract][Full Text] [Related]
9. Evaluating interactions of polygenic risk scores and NAT2 genotypes with tobacco smoking in bladder cancer risk.
Pradhan P; Jia G; Khankari NK; Zheng W
Int J Cancer; 2024 Jan; 154(2):210-216. PubMed ID: 37728483
[TBL] [Abstract][Full Text] [Related]
10. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese.
Inatomi H; Katoh T; Kawamoto T; Matsumoto T
Int J Urol; 1999 Sep; 6(9):446-54. PubMed ID: 10510890
[TBL] [Abstract][Full Text] [Related]
11. N-acetyltransferase 2 polymorphism is associated with bladder cancer risk: An updated meta-analysis based on 54 case-control studies.
Song Y; Qi X; Liu X
Gene; 2020 Oct; 757():144924. PubMed ID: 32622992
[TBL] [Abstract][Full Text] [Related]
12. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
13. White Blood Cells and Blood Pressure: A Mendelian Randomization Study.
Siedlinski M; Jozefczuk E; Xu X; Teumer A; Evangelou E; Schnabel RB; Welsh P; Maffia P; Erdmann J; Tomaszewski M; Caulfield MJ; Sattar N; Holmes MV; Guzik TJ
Circulation; 2020 Apr; 141(16):1307-1317. PubMed ID: 32148083
[TBL] [Abstract][Full Text] [Related]
14. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
Stern MC; Johnson LR; Bell DA; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
Koutros S; Kiemeney LA; Pal Choudhury P; Milne RL; Lopez de Maturana E; Ye Y; Joseph V; Florez-Vargas O; Dyrskjøt L; Figueroa J; Dutta D; Giles GG; Hildebrandt MAT; Offit K; Kogevinas M; Weiderpass E; McCullough ML; Freedman ND; Albanes D; Kooperberg C; Cortessis VK; Karagas MR; Johnson A; Schwenn MR; Baris D; Furberg H; Bajorin DF; Cussenot O; Cancel-Tassin G; Benhamou S; Kraft P; Porru S; Carta A; Bishop T; Southey MC; Matullo G; Fletcher T; Kumar R; Taylor JA; Lamy P; Prip F; Kalisz M; Weinstein SJ; Hengstler JG; Selinski S; Harland M; Teo M; Kiltie AE; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Schned A; Lenz P; Riboli E; Brennan P; Tjønneland A; Otto T; Ovsiannikov D; Volkert F; Vermeulen SH; Aben KK; Galesloot TE; Turman C; De Vivo I; Giovannucci E; Hunter DJ; Hohensee C; Hunt R; Patel AV; Huang WY; Thorleifsson G; Gago-Dominguez M; Amiano P; Golka K; Stern MC; ; Yan W; Liu J; Li SA; Katta S; Hutchinson A; Hicks B; Wheeler WA; Purdue MP; McGlynn KA; Kitahara CM; Haiman CA; Greene MH; Rafnar T; Chatterjee N; Chanock SJ; Wu X; Real FX; Silverman DT; Garcia-Closas M; Stefansson K; Prokunina-Olsson L; Malats N; Rothman N
Eur Urol; 2023 Jul; 84(1):127-137. PubMed ID: 37210288
[TBL] [Abstract][Full Text] [Related]
16. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
Wu H; Wang X; Zhang L; Mo N; Lv Z
Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort.
Fontana L; Delort L; Joumard L; Rabiau N; Bosviel R; Satih S; Guy L; Boiteux JP; Bignon YJ; Chamoux A; Bernard-Gallon DJ
Anticancer Res; 2009 May; 29(5):1631-5. PubMed ID: 19443378
[TBL] [Abstract][Full Text] [Related]
18. N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population.
Hosen MB; Islam J; Salam MA; Islam MF; Hawlader MZ; Kabir Y
Asia Pac J Clin Oncol; 2015 Mar; 11(1):78-84. PubMed ID: 25376209
[TBL] [Abstract][Full Text] [Related]
19. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
[TBL] [Abstract][Full Text] [Related]
20. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
Cascorbi I; Roots I; Brockmöller J
Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
